The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Open accessAbstract
BACKGROUND: Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination. METHODS: ). RESULTS: aberration, or chromosome 11q deletion. With combined treatment, the proportions of patients who had complete remission (with or without normal blood count recovery) and remission with undetectable minimal residual disease increased over time. After 12 cycles of combined treatment, 88% of the patients had complete remission or complete remission with incomplete count recovery, and 61% had remission with undetectable minimal residual disease. Responses were noted in older adults and across all high-risk subgroups. Three patients had laboratory evidence of tumor lysis syndrome. The adverse-event profile was similar to what has been reported with ibrutinib and venetoclax. CONCLUSIONS: In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Self-citationObinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Tumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Self-citationVenetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Eichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
Rawstron, A. C., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J. L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404584 · Cited by 403
O’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
Self-citationHallek, M., Shanafelt, T. D., & Eichhorst, B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30422-7 · Cited by 370
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S., Jurczak, W., Mulligan, S. P., Schuh, A., Assouline, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6840 · Cited by 314
Self-citationBrown, J. R., Moslehi, J., O’Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Kipps, T. J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.171041 · Cited by 267
Self-citationCervantes-Gomez, F., Lamothe, B., Woyach, J. A., Wierda, W. G., Keating, M. J., Balakrishnan, K., & Gandhi, V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2809 · Cited by 222
Self-citationDepth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Deng, J., Isik, E., Fernandes, S. M., Brown, J. R., Letai, A., & Davids, M. S. (2017) · Leukemia · doi:10.1038/leu.2017.32 · Cited by 202
Dimier, N., Delmar, P., Ward, C., Morariu-Zamfir, R., Fingerle‐Rowson, G., Bahlo, J., Fischer, K., Eichhorst, B. F., Goede, V., van Dongen, J. J. M., et al. (2017) · Blood · doi:10.1182/blood-2017-06-792333 · Cited by 83
Selecting Frontline Therapy for CLL in 2018
Jain, N. (2018) · Hematology · doi:10.1182/asheducation-2018.1.242 · Cited by 16
Self-citation
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Metadata
- Authors
- Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., Konopleva, M., Alvarado, Y., Yilmaz, M., DiNardo, C., Bose, P., Ohanian, M., Pemmaraju, N., Jabbour, E., Sasaki, K., Kanagal-Shamanna, R., Patel, K., Jorgensen, J., Garg, N., Wang, X., Sondermann, K., Cruz, N., Wei, C., Ayala, A., Plunkett, W., Kantarjian, H., Gandhi, V., & Wierda, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-30
- Volume
- 380
- Issue
- 22
- Pages
- 2095-2103
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2946882253
- Cited by
- 509
- References
- 24
- FWCI
- 39.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.